Exjade is a Oral Tablet, For Suspension in the Human Prescription Drug category. It is labeled and distributed by Novartis Pharmaceuticals Corporation. The primary component is Deferasirox.
Product ID | 0078-0469_12e80115-bfb7-4292-89cc-e696a3c6c325 |
NDC | 0078-0469 |
Product Type | Human Prescription Drug |
Proprietary Name | Exjade |
Generic Name | Deferasirox |
Dosage Form | Tablet, For Suspension |
Route of Administration | ORAL |
Marketing Start Date | 2005-11-30 |
Marketing Category | NDA / NDA |
Application Number | NDA021882 |
Labeler Name | Novartis Pharmaceuticals Corporation |
Substance Name | DEFERASIROX |
Active Ingredient Strength | 250 mg/1 |
Pharm Classes | Iron Chelating Activity [MoA],Iron Chelator [EPC],Cytochrome P450 3A4 Inducers [MoA],Cytochrome P450 2C8 Inhibitors [MoA],Cytochrome P450 1A2 Inhibitors [MoA] |
NDC Exclude Flag | N |
Listing Certified Through | 2022-12-31 |
Marketing Start Date | 2005-11-30 |
NDC Exclude Flag | N |
Sample Package? | N |
Marketing Category | NDA |
Application Number | NDA021882 |
Product Type | HUMAN PRESCRIPTION DRUG |
Billing Unit | EA |
Marketing Start Date | 2005-11-30 |
Ingredient | Strength |
---|---|
DEFERASIROX | 250 mg/1 |
SPL SET ID: | 3495a70c-870c-4968-940e-8baea152cf85 |
Manufacturer | |
UNII | |
RxNorm Concept Unique ID - RxCUI |
NDC | Brand Name | Generic Name |
---|---|---|
0078-0468 | Exjade | deferasirox |
0078-0469 | Exjade | deferasirox |
0078-0470 | Exjade | deferasirox |
0078-0654 | Jadenu | deferasirox |
0078-0655 | Jadenu | deferasirox |
0078-0656 | Jadenu | deferasirox |
Mark Image Registration | Serial | Company Trademark Application Date |
---|---|
EXJADE 88575851 not registered Live/Pending |
QINGDAO YUZHUO COSMETIC PRODUCTS CO., LTD 2019-08-12 |
EXJADE 78304307 2875038 Live/Registered |
NOVARTIS AG 2003-09-23 |
EXJADE 78089460 2773531 Dead/Cancelled |
Novartis AG 2001-10-22 |